Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish R Sharma

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Nature Reviews. Clinical Oncology|February 1, 2011
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapyManish R Sharma, Richard L Schilsky
Nature Reviews. Clinical Oncology|December 7, 2011
Role of randomized phase III trials in an era of effective targeted therapiesManish R Sharma, Richard L Schilsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2015
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical TrialsManish R Sharma, Mark J Ratain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 22, 2020
The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and PayloadsValentina Boni, Manish R Sharma, Amita Patnaik
Neoplasia (New York, N.Y.)|February 6, 2025
An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumorsRussell J Schilder, Drew Rasco, Manish R Sharma
Journal of the National Cancer Institute|June 29, 2011
Randomized phase II trials: a long-term investment with promising returnsManish R Sharma, Walter M Stadler, Mark J Ratain
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studiesManish R Sharma, Michael L Maitland, Mark J Ratain
Cancer Research|September 7, 2012
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---pointManish R Sharma, Michael L Maitland, Mark J Ratain
American Journal of Clinical Oncology|June 28, 2017
Capecitabine and Celecoxib as a Promising Therapy for Thymic NeoplasmsKevin Wood, Elizabeth Byron, Linda Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsManish R Sharma, Elizabeth Gray, Richard M Goldberg, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Nature Reviews. Clinical Oncology|February 1, 2011
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapyManish R Sharma, Richard L Schilsky
Nature Reviews. Clinical Oncology|December 7, 2011
Role of randomized phase III trials in an era of effective targeted therapiesManish R Sharma, Richard L Schilsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2015
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical TrialsManish R Sharma, Mark J Ratain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 22, 2020
The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and PayloadsValentina Boni, Manish R Sharma, Amita Patnaik
Neoplasia (New York, N.Y.)|February 6, 2025
An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumorsRussell J Schilder, Drew Rasco, Manish R Sharma
Journal of the National Cancer Institute|June 29, 2011
Randomized phase II trials: a long-term investment with promising returnsManish R Sharma, Walter M Stadler, Mark J Ratain
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studiesManish R Sharma, Michael L Maitland, Mark J Ratain
Cancer Research|September 7, 2012
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---pointManish R Sharma, Michael L Maitland, Mark J Ratain
American Journal of Clinical Oncology|June 28, 2017
Capecitabine and Celecoxib as a Promising Therapy for Thymic NeoplasmsKevin Wood, Elizabeth Byron, Linda Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsManish R Sharma, Elizabeth Gray, Richard M Goldberg, et al.
Pageof 5